RNAi gets boost with Roche acquisition of Mirus Bio

07/22/2008 | Reuters

Roche Holding purchased Mirus Bio Corp. in a $125 million deal that grants it access to the U.S. firm's gene-silencing technology. The acquisition brings the Swiss drugmaker "closer to creating fully enabled RNAi therapeutics," a Roche official said.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA